CD282 Antibody [mT2.7] (FITC)

Product Specifications

Background

The mT2.7 monoclonal antibody specifically reacts with mouse CD282, the Toll-like receptor 2 (TLR2) . It is a type I transmembrane signaling receptor containing IL-1 receptor like intracellular domain and leucine-rich repeats (LRR) in the extracellular domain. CD282 is expressed on monocytes, macrophages, dendritic cells, and the RAW264.7 cell line and is involved distinguishing bacterial lipoproteins.

NCBI Gene ID

24088

Swiss Prot

Q9QUN7

Host

Mouse

Reactivity

Mouse

Clonality

Monoclonal

Clone

MT2.7

Conjugation

FITC

Type

Primary Antibodies

Field of Research

Innate Immunity

Purification

The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.

Concentration

Batch dependent

Buffer

Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

The product should be stored undiluted at 4˚ C and should be protected from prolonged exposure to light. Do not freeze.

Fragment

Mouse IgG2a, kappa

Specificity

The mT2.7 monoclonal antibody specifically reacts with mouse CD282, the Toll-like receptor 2 (TLR2) .

Symbol

Tlr2

NCBI Official Name

Toll-like receptor 2

NCBI Organism

Mus musculus

Background Reference 01

Mechetner, E. B., Roninson, I. B. (1992) . Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.Proceedings of the National Academy of Sciences,89 (13), 5824-5828.

Background Reference 02

Chaudhary, P. M., Mechetner, E. B., Roninson, I. B. (1992) . Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes [see comments].Blood,80 (11), 2735-2739.

Background Reference 03

Goda, K., Fenyvesi, F., Bacs, Z., Nagy, H., Mrin, T., Megyeri, A., ... Szab, G. (2007) . Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody.Journal of Pharmacology and Experimental Therapeutics,320 (1), 81-88.